Halaven® (eribulin) injection is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer which has continued to spread after at least two previous treatment for advanced cancer. Previous treatment should have included anthracyclines and a taxane in either the adjuvant or metastatic setting, unless these treatments were not suitable. Halaven®(eribulin) injection is also used to treat patients with advanced or metastatic liposarcoma that cannot be surgically removed. It is used in patients who have already been treated with an anthracycline, unless deemed unsuitable.
Halaven® (eribulin) injection has shown to significantly improve overall survival in patients with advanced or metastatic breast cancer after anthracycline and taxane treatment. Halaven® (eribulin) injection indicated extended overall survival (OS) of 2.5 months (OS of 13.1 months versus 10.6 months, respectively;
Breast cancer is now the most frequently diagnosed cancer in Colombian women. In 2020, an estimated 15,509 patients were diagnosed with breast cancer3. Further, approximately 1,500 patients in
“We’re pleased to announce the approval of Halaven® (eribulin) injection in
Knight has an exclusive license from Eisai to commercialize Lenvima® (lenvatinib), Halaven® (eribulin) injection, Fycompa® (perampanel), and Inovelon® (rufinamide) throughout
About Halaven® (eribulin) injection
Discovered and developed by Eisai, eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai. First in the halichondrin class, eribulin is a microtubule dynamics inhibitor. Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death. Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumor biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype5-6. Eribulin has also been shown to decrease the migration and invasiveness of human breast cancer cells5-6.
About
Forward-Looking Statement
This document contains forward-looking statements for
Investor Contact: | |
Arvind Utchanah | |
President & Chief Executive Officer | Chief Financial Officer |
T: 514.484.4483 | T. 514.484.4483 |
F: 514.481.4116 | F. 514.481.4116 |
Email: info@knighttx.com | Email: info@knighttx.com |
Website: www.gud-knight.com | Website: www.gud-knight.com |
References:
- Cortes J et al., Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Lancet, 2011; 377, 914-23
- Schöffski P et al. Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). American Society of Clinical Oncology annual meeting 2015; Abstract #LBA10502
- Cancer today. Gco.iarc.fr. (2021). Retrieved
2 November 2021 , from https://gco.iarc.fr/today/online-analysis table?v=2020&mode=cancer&mode_population=continents&population=900&populations=170&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1 - Ducimetière, F., Lurkin, A., Ranchère-Vince, D., Decouvelaere, A., Péoc'h, M., & Istier, L. et al. (2011). Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing. Plos ONE, 6(8), e20294. https://doi.org/10.1371/journal.pone.0020294
- Funahashi Y et al., Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci., 2014; 105, 1334-1342
- Yoshida T et al., Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer, 2014; 110, 1497-1505
Source:
2022 GlobeNewswire, Inc., source